Pearl Therapeutics

Pearl, which is now a member of the AstraZeneca Group, was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilising a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).

 

In 2007, Pearl began the development of leading product candidates with initial venture funding from 5AM Ventures, Clarus Ventures and New Leaf Ventures. In 2010, Vatera Healthcare Partners joined Pearl as a fourth investor. Between 2007-2013, Pearl’s four investors backed it with $167.5 million, allowing the progression of key therapeutic areas.

Subsequently, in 2013, AstraZeneca acquired Pearl to expand and strengthen its respiratory products portfolio, which includes many Pearl legacy compounds, and have made strides in bringing therapies to asthma patients.

Notably, Pearl’s lead combination medicine was recently launched in the US during the first quarter of 2017 and has regulatory submission acceptance in EU for COPD. Thanks to the Pearl team’s experience as inhalation product development experts, another lead product candidate is progressing through the pipeline as a potential treatment for COPD and asthma.


2020欧洲杯体育足球滚球比分Pearl successfully delivered valuable therapeutics for a range of respiratory patients. As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.

Colin ReisnerHead of Respiratory Global Medicines Development and CEO of Pearl Therapeutics

AstraZeneca's Respiratory & Immunology pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Respiratory & Immunology (as at 29 April 2020)

Phase I

Phase I

  • AZD0284psoriasis/respiratory
  • AZD0449asthma
  • AZD1402asthma
  • AZD5634cystic fibrosis
  • AZD8154asthma
  • MEDI5117 Chinarheumatoid arthritis

Phase II

Phase II

  • abediterolasthma/chronic obstructive pulmonary disease
  • anifrolumablupus nephritis
  • anifrolumabsystemic lupus erythematosus (subcutaneous)
  • AZD7986chronic obstructive pulmonary disease
  • AZD9567rheumatoid arthritis/respiratory
  • MEDI3506chronic obstructive pulmonary disease and atopic dermatitis
  • navafenterol (AZD8871)chronic obstructive pulmonary disease
  • tezepelumabatopic dermatitis
  • tezepelumabchronic obstructive pulmonary disease
  • velsecorat (AZD7594)asthma/chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumabTULIPsystemic lupus erythematosus
  • Bevespi Aerosphere (PT003)chronic obstructive pulmonary disease
  • Breztri Aerosphere (PT010)chronic obstructive pulmonary disease
  • FasenraCALIMA SIROCCO ZONDA BISE BORAGREGALE MIRACLEsevere uncontrolled asthma
  • nirsevimabpassive RSV immunisation
  • PT027asthma
  • tezepelumabNAVIGATOR SOURCEsevere uncontrolled asthma

2020欧洲杯体育足球滚球比分LCM Projects

LCM Projects

  • Breztri (PT010)asthma
  • Duaklir Genuairchronic obstructive pulmonary disease
  • FasenraMANDARAeosinophilic granulomatosis with polyangiitis
  • FasenraOSTROORCHID (Japan/China)nasal polyposis
  • FasenraRESOLUTEchronic obstructive pulmonary disease
  • SymbicortSYGMAas-needed use in mild asthma

Job Postings - Pearl